



ASX Announcement

April 15th 2024

Atomo secures significant order for HIV Self-Tests for LMIC Territories

SYDNEY, Australia April 15th, 2024 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce securing purchase orders from Viatris Healthcare Pty Ltd (Viatris) for approximately \$570,000 worth of HIV Self-Tests, manufactured by Atomo under the Mylan brand for supply to several Low- and Middle-Income Countries (LMICs). The orders are for manufacture in the coming months. Atomo considers the revenue from these orders to be material.

Mr Kelly said, "We are delighted to see Viatris, our global health partner, continues to secure orders across LMIC markets. Recent growth in our global health markets mirrors anticipated growth here in Australia from emerging public health channels, and we are encouraged by the ongoing transition of diagnostic testing demand from healthcare facilities to self-test channels."

This announcement was authorised by the Managing Director & CEO.

For more information, please contact:

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health.

See more at www.atomodiagnostics.com